Lincomycin, the first of two lincosamide antimicrobial agents, was isolated in 1962 from a soil actinomycete found near Lincoln, Nebraska, which gave origin to its name. The actinomycete was classified as Streptomyces lincolnensis var. lincolnensis, a new streptomycete species. Initial reports indicated that lincomycin possessed good in vitro and in vivo potency against a variety of Gram-positive microorganisms. It did not exhibit cross resistance with known antibiotics and possessed a low degree of toxicity. Lincomycin has gained clinical acceptance as a major antibiotic for the treatment of diseases caused by Gram-positive microbes.
CDIATM Lincomycin Test Kit is based on competitive indirect colloid gold immunochromatography technology, in which lincomycin in sample competes for the colloid gold labeled antibody with lincomycin coupling antigen captured on test line. The test result can be observed by naked eye.